April 28, 2023
No drama here
With each passing earnings call it’s getting more difficult to say the same thing in a different way. And quite frankly it doesn’t matter whose earnings are being released Abbott or in this case Dexcom. The CGM market is their domain, they own it, will continue to own it and barring a major screw up will own it for quite some time. Their systems are only getting better, access to their systems continues to improve while the market beyond diabetes creates even greater opportunities.
Frankly we aren’t sure why shares are down in pre-market this morning . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
